Clinical Trial Detail

NCT ID NCT01843062
Title Study Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer
Recruitment Terminated
Gender both
Phase Phase III
Variant Requirements No
Sponsors AstraZeneca
Indications

thyroid gland cancer

Therapies

Selumetinib

Age Groups: adult

No variant requirements are available.